Trial: 201805175

An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Phase

N/A (Cancer Control)

Principal Investigator

Dipersio, John

Disease Site

Bone Marrow Transplant; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov